
Quarterly report 2025-Q3
added 11-06-2025
DENTSPLY SIRONA Cash Flow 2011-2026 | XRAY
Annual Cash Flow DENTSPLY SIRONA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
461 M | 377 M | 517 M | 657 M | 649 M | 639 M | 500 M | 602 M | 563 M | 497 M | 560 M | 418 M | 370 M | 393 M |
Depreciation & Amortization |
349 M | 343 M | 328 M | 347 M | 334 M | 323 M | 331 M | 316 M | 272 M | 123 M | 129 M | 128 M | 129 M | 85 M |
Accounts Payables |
241 M | 305 M | 279 M | 262 M | 302 M | 308 M | 284 M | 284 M | 223 M | 134 M | 133 M | 133 M | 165 M | 149 M |
Total Inventories |
564 M | 624 M | 627 M | 515 M | 476 M | 562 M | 599 M | 623 M | 517 M | 340 M | 387 M | 439 M | 403 M | 362 M |
All numbers in USD currency
Quarterly Cash Flow DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 7 M | - | - | - | 25 M | - | - | - | -21 M | - | 375 M | 266 M | 93 M | - | 435 M | 263 M | 49 M | - | 372 M | 164 M | -10 M | - | 334 M | 174 M | 29.3 M | - | 298 M | 172 M | 55.1 M | - | 373 M | 209 M | 82.5 M | - | 341 M | 188 M | 700 K | - | 371 M | 211 M | 65.6 M | - | 368 M | 220 M | 64.6 M | - | 258 M | 132 M | 36.1 M | - | 202 M | 103 M | 20 M | - | 255 M | 167 M | 44.7 M |
Depreciation & Amortization |
92 M | 88 M | 79 M | - | 89 M | 86 M | 86 M | - | - | - | 31 M | - | 90 M | 59 M | 29 M | - | 94 M | 64 M | 32 M | - | 104 M | 65 M | 32 M | - | 102 M | 70.4 M | 34.9 M | - | 103 M | 68.8 M | 33.3 M | - | 93.9 M | 62.1 M | 30.9 M | - | 87 M | 55.1 M | 23.5 M | - | 61.6 M | 38.8 M | 19.3 M | - | 63.1 M | 42.3 M | 21.4 M | - | 61.5 M | 41.7 M | 20.4 M | - | 59.5 M | 40.4 M | 20.2 M | - | 47.1 M | 32.4 M | 15.2 M |
Accounts Payables |
268 M | 268 M | 276 M | 241 M | 297 M | 287 M | 279 M | 305 M | 262 M | 265 M | 267 M | 279 M | 271 M | 289 M | 277 M | 262 M | 276 M | 281 M | 262 M | 305 M | 305 M | 305 M | 305 M | 308 M | 308 M | 308 M | 308 M | 284 M | 284 M | 284 M | 284 M | 284 M | 284 M | 284 M | 284 M | 223 M | 223 M | 223 M | 223 M | 134 M | 134 M | 134 M | 134 M | 133 M | 133 M | 133 M | 133 M | 133 M | 133 M | 133 M | 133 M | 165 M | 165 M | 165 M | 165 M | 149 M | 149 M | 149 M | 149 M |
Total Inventories |
686 M | 675 M | 612 M | 564 M | 619 M | 608 M | 613 M | 624 M | 651 M | 657 M | 659 M | 627 M | 592 M | 581 M | 553 M | 515 M | 532 M | 539 M | 515 M | 466 M | 466 M | 466 M | 466 M | 562 M | 562 M | 562 M | 562 M | 599 M | 599 M | 599 M | 599 M | 623 M | 623 M | 623 M | 623 M | 517 M | 517 M | 517 M | 517 M | 340 M | 340 M | 340 M | 340 M | 387 M | 387 M | 387 M | 387 M | 439 M | 439 M | 439 M | 439 M | 403 M | 403 M | 403 M | 403 M | 362 M | 362 M | 362 M | 362 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company DENTSPLY SIRONA , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 20.1 | 1.85 % | $ 10.3 B | ||
|
ICU Medical
ICUI
|
$ 148.85 | -0.79 % | $ 3.63 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.57 | 2.15 % | $ 173 M | ||
|
Alcon
ALC
|
$ 81.03 | -0.12 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
$ 5.39 | -1.1 % | $ 246 M | ||
|
AtriCure
ATRC
|
$ 36.9 | -0.14 % | $ 1.73 B | ||
|
Haemonetics Corporation
HAE
|
$ 66.55 | 0.88 % | $ 3.35 B | ||
|
electroCore
ECOR
|
$ 6.6 | -7.04 % | $ 36.4 K | ||
|
AngioDynamics
ANGO
|
$ 10.3 | 3.21 % | $ 421 M | ||
|
InfuSystem Holdings
INFU
|
$ 8.27 | 2.73 % | $ 171 M | ||
|
OraSure Technologies
OSUR
|
$ 2.78 | -0.54 % | $ 207 M | ||
|
The Cooper Companies
COO
|
$ 81.34 | 1.21 % | $ 16.2 B | ||
|
Masimo Corporation
MASI
|
$ 137.49 | 0.91 % | $ 7.33 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.5 | -6.73 % | $ 21.2 M | ||
|
Glaukos Corporation
GKOS
|
$ 119.29 | 0.28 % | $ 5.78 B | ||
|
Merit Medical Systems
MMSI
|
$ 80.93 | 0.85 % | $ 4.71 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
iRhythm Technologies
IRTC
|
$ 154.21 | 3.5 % | $ 4.81 B | ||
|
LeMaitre Vascular
LMAT
|
$ 84.97 | 1.32 % | $ 1.91 B | ||
|
STERIS plc
STE
|
$ 261.9 | 0.02 % | $ 25.8 B | ||
|
Intuitive Surgical
ISRG
|
$ 505.17 | -0.47 % | $ 179 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Microbot Medical
MBOT
|
$ 1.81 | -2.96 % | $ 18.5 M | ||
|
Utah Medical Products
UTMD
|
$ 61.21 | -0.71 % | $ 222 M | ||
|
Nephros
NEPH
|
$ 4.35 | -0.91 % | $ 45.2 M | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | -2.67 % | $ 23.1 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.4 | 0.13 % | $ 4.03 B | ||
|
Pro-Dex
PDEX
|
$ 38.77 | -1.61 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
$ 13.76 | 0.99 % | $ 661 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 203.2 | 1.05 % | $ 58.5 B | ||
|
Repligen Corporation
RGEN
|
$ 150.44 | -3.8 % | $ 8.38 M | ||
|
ResMed
RMD
|
$ 256.15 | -0.57 % | $ 37.4 B | ||
|
BioLife Solutions
BLFS
|
$ 21.91 | -2.97 % | $ 1.01 B | ||
|
Stereotaxis
STXS
|
$ 2.21 | -5.36 % | $ 178 M | ||
|
Retractable Technologies
RVP
|
$ 0.7 | -1.03 % | $ 21 M | ||
|
STAAR Surgical Company
STAA
|
$ 18.9 | -0.24 % | $ 928 M | ||
|
Teleflex Incorporated
TFX
|
$ 104.44 | -0.96 % | $ 4.89 B | ||
|
West Pharmaceutical Services
WST
|
$ 231.57 | -0.4 % | $ 16.9 B |